Pfizer and Strides Arcolab have entered into a new collaboration, wherein Pfizer is expected to commercialise off-patent sterile injectable and oral products in the US through its Products Business unit.
Reportedly, the finished dosage form products will be licensed and supplied by Strides and Onco Laboratories and Onco Therapies. Two joint ventures between Strides and Aspen has been made in which each has a 50% ownership interest. The financial terms of the supply agreement were not disclosed.
The companies are expected to deliver 40 off-patent products, many of which are oncology therapeutics, to healthcare providers and patients in the US, by joining Pfizer’s commercial infrastructure with Strides’s manufacturing capabilities. The first of the products commercialised under the collaboration is expected to be launched in 2010.
Arun Kumar, founder and managing director of Strides Arcolab, said: “Partnering with Pfizer enhances our ability to reach a larger base of customers and patients in need of quality treatment options. We are looking forward to bringing our strengths to bear in our collaboration with Pfizer.”